With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.

The latest label expansion for Novartis’s Fabhalta (iptacopan), for C3 glomerulopathy (C3G), allows the firm to expand its growing presence in the renal disease space, which the Swiss drug maker will do by employing digital technology and artificial intelligence to reach patients with the rare kidney disease.

The US Food and Drug Administration approved Fabhalta, a complement factor B inhibitor, on 20 March for reducing proteinuria in...